Actual cost of providing long-acting reversible contraception: A study of Implanon® cost

Journal of Family Planning and Reproductive Health Care

Volumn 35, Issue 2, 2009, Pages 75-79

  Lipetz, Clare ^a   Phillips, Ceri ^b   Fleming, Charlotte ^a  

^a ANEURIN BEVAN UNIVERSITY HEALTH BOARD   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Cost analysis; Implanon ; LARC; Long acting reversible contraception

Indexed keywords

GESTAGEN; MEFENAMIC ACID; ORAL CONTRACEPTIVE AGENT; TRANEXAMIC ACID;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BLEEDING; CONSULTATION; CONTRACEPTION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEVICE REMOVAL; DRUG COST; FEMALE; FEMALE CONTRACEPTIVE DEVICE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; LONG ACTING REVERSIBLE CONTRACEPTION; MEDICAL EDUCATION; MEDICAL EXAMINATION; NURSING COST; PREGNANCY RATE; PREGNANCY TERMINATION; PREGNANCY TEST; PRESCRIPTION;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; YOUNG ADULT;

EID: 65249161099     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118909787931555     Document Type: Article

References (12)

1. National Institute for Health and Clinical Excellence. Long-Acting Reversible Contraception (Clinical Guideline CG30). October 2005. http://www.nice.org.uk/Guidance/CG30/Guidance/pdf/English [Accessed 5 July 2008].
2. Department of Health Statistical Bulletin. Abortion Statistics, England and Wales: 2006. http://www.statistics.gov.uk/downloads/ theme-health/Conceptions2006/annualconceptions_2006.xls [Accessed 5 July 2008].
3. National Institute for Health and Clinical Excellence (NICE). National Cost Impact Report: Implementing the NICE Guideline on Long-Acting Reversible Contraception. December 2005. http://www.nice.org.uk/nicemedia/pdf/CG030costing.pdf [Accessed 5 July 2008].
4. Mapping the Patient Pathway (unpublished departmental data). Gwent, UK: Gwent Sexual and Reproductive Health, 2006.
5. Faculty of Sexual and Reproductive Health Workforce Planning Committee. The Ninth and Tenth Census of the Family Planning Workforce in the United Kingdom 2005 and 2006. January 2007. www.ffprhc.org.uk/admin/ uploads/CENSUS0506.pdf [Accessed 5 July 2008].
6. Curtis L, Netten A. Unit Costs of Health and Social Care 2004. Canterbury, UK: Personal Social Services Research Unit, University of Kent at Canterbury, 2004.
7. Department of Health. Sexual health general information: contraception. 2009. http://www.dh.gov.uk/en/Publichealth/Healthimprovement/ Sexualhealth/Sexualhealthgeneralinformation/DH_4001998 [Accessed 5 July 2008].
8. Rai K, Gupta S, Cotter S. Experience with Implanon® in a north-east London family planning clinic. Eur J Contracept Reprod Health Care 2004; 9: 39-46.
9. Varney S, Guest J. Relative cost effectiveness of DepoProvera injection, Implanon and Mirena in reversible long term hormonal contraception in the UK. Pharmacoeconomics 2004; 22: 1141-1151.
10. Lakha F, Glasier A. Continuation rates of Implanon® in the UK: data from an observational study in a clinical setting. Contraception 2006; 74: 287-289.
11. French RS, Cowan FM, Mansour DJ, Morris S, Procter T, Hughes D, et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol Assess 2000; 4 (7)j-v: 1-107.
12. Armstrong N, Cavey C, Donaldson C. The Economics of Sexual Health. London, UK: fpa, 2005.